Inhibition	O
of	O
MHC-	B:C0019629
I	I:C0019629
by	O
Brucella	B:C0006304
abortus	I:C0006304
is	O
an	O
early	O
event	O
during	O
infection	B:C3714514
and	O
involves	O
EGFR	B:C1155379
pathway	I:C1155379
.	O

Brucella	B:C0006304
abortus	I:C0006304
is	O
able	O
to	O
persist	O
inside	O
the	O
host	O
despite	O
the	O
development	O
of	O
potent	O
CD8	B:C0242629
(+	I:C0242629
)	I:C0242629

T	I:C0242629
-	I:C0242629
cell	I:C0242629
responses	B:C0007613
.	O

We	O
have	O
recently	O
reported	O
the	O
ability	O
of	O
B.	B:C0006304
abortus	I:C0006304
to	O
inhibit	O
the	O
interferon-γ	B:C0021745
-	O
induced	O
major	B:C0019629
histocompatibility	I:C0019629
complex	I:C0019629
(	I:C0019629
MHC	I:C0019629
)	I:C0019629
-	I:C0019629
I	I:C0019629
cell	B:C0699040
surface	I:C0699040
expression	B:C1171362
on	O
human	B:C0086418
monocytes	B:C0026473
.	O

This	O
phenomenon	O
was	O
due	O
to	O
the	O
B.	B:C0006304
abortus	I:C0006304
-	O
mediated	O
retention	B:C1753315
of	O
MHC	B:C0019629
-	I:C0019629
I	I:C0019629
molecules	O
within	O
the	O
Golgi	B:C0018042
apparatus	I:C0018042
and	O
was	O
dependent	O
on	O
bacterial	O
viability	O
.	O

However	O
,	O
the	O
implications	O
of	O
bacterial	O
virulence	O
or	O
replicative	O
capacity	O
and	O
the	O
signaling	B:C0037080
pathways	I:C0037080
remained	O
unknown	O
.	O

Here	O
we	O
demonstrated	O
that	O
the	O
B.	B:C0006304
abortus	I:C0006304
mutant	O
strains	O
RB51	B:C2316069
and	O
virB10	B:C1513916
(	I:C1513916
-)	I:C1513916
are	O
able	O
to	O
inhibit	O
MHC	B:C0019629
-	I:C0019629
I	I:C0019629
expression	B:C1171362
in	O
the	O
same	O
manner	O
as	O
wild	B:C1883559
-	I:C1883559
type	I:C1883559
B.	B:C0006304
abortus	I:C0006304
,	O
even	O
though	O
they	O
are	O
unable	B:C1299582
to	O
persist	O
inside	O
human	B:C0086418
monocytes	B:C0026473
for	O
a	O
long	O
period	O
of	O
time	O
.	O

Consistent	O
with	O
this	O
,	O
the	O
phenomenon	O
was	O
triggered	O
early	O
in	O
time	O
and	O
could	O
be	O
observed	O
at	O
8	O
h	O
postinfection	B:C0021387
.	O

Regarding	O
the	O
signaling	B:C0037080
pathway	I:C0037080
,	O
targeting	B:C1159372
epidermal	B:C0242275
growth	I:C0242275
factor	I:C0242275
(	O
epidermal	B:C0242275
growth	I:C0242275
factor	I:C0242275
)	O
receptor	B:C0034802
(	O
EGFR	B:C0034802
)	O
,	O
ErbB2	B:C0069515
(	O
HER2	B:C0069515
)	O
or	O
inhibition	O
of	O
tumor	B:C0041368
necrosis	I:C0041368
factor	I:C0041368
-	O
α-	B:C1569773
converting	I:C1569773
enzyme	I:C1569773
,	O
one	O
of	O
the	O
enzymes	B:C0014442
which	O
generates	O
soluble	O
EGF	B:C3849998
-	I:C3849998
like	I:C3849998
ligands	I:C3849998
,	O
resulted	O
in	O
partial	O
recovery	O
of	O
MHC	B:C0019629
-	I:C0019629
I	I:C0019629
surface	B:C0699040
expression	B:C1171362
.	O

Moreover	O
,	O
recombinant	B:C0034861
EGF	I:C0034861
and	O
transforming	B:C0040688
growth	I:C0040688
factor	I:C0040688
-α	I:C0040688
as	O
well	O
as	O
the	O
combination	O
of	O
both	O
were	O
also	O
able	O
to	O
reproduce	B:C0035150
the	O
B.	B:C0006304
abortus	I:C0006304
-	O
induced	O
MHC	B:C0019629
-	I:C0019629
I	I:C0019629
downmodulation	O
.	O

Finally	O
,	O
when	O
infection	B:C3714514
was	O
performed	O
in	O
the	O
presence	O
of	O
an	O
extracellular	B:C0600388
signal	I:C0600388
-	I:C0600388
regulated	I:C0600388
kinase	I:C0600388
1/2	I:C0600388
(	O
extracellular	B:C0600388
signal	I:C0600388
-	I:C0600388
regulated	I:C0600388
kinase	I:C0600388
1/2	I:C0600388
)	O
inhibitor	B:C0014432
,	O
MHC	B:C0019629
-	I:C0019629
I	I:C0019629
surface	B:C0699040
expression	B:C1171362
was	O
significantly	O
recovered	O
.	O

Overall	O
,	O
these	O
results	O
describe	O
how	O
B.	B:C0006304
abortus	I:C0006304
evades	O
CD8	B:C0242629
(+)	I:C0242629

T	I:C0242629
-	I:C0242629
cell	I:C0242629
responses	B:C0007613
early	O
during	O
infection	B:C3714514
and	O
exploits	O
the	O
EGFR	B:C0034802
-	O
ERK	B:C0600388
signaling	B:C0037080
pathway	I:C0037080
to	O
escape	O
from	O
the	O
immune	B:C0020962
system	I:C0020962
and	O
favor	O
chronicity	O
.	O

